Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma reported Week 182 data from the Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in hypopara | Jun 15, 2026 |
| EOLS | EFFECT | neutral | 3/10 | Evolus's S-3 shelf registration (File No. 333-296556) went effective on June 12, 2026, enabling the company to conduct o | Jun 15, 2026 |
| BLTE | 6-K | bullish | 6/10 | Belite Bio completed rolling submission of its New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy fo | Jun 15, 2026 |
| SNSE | EFFECT | bearish | 6/10 | The SEC declared effective Sensei Biotherapeutics' S-3 shelf registration on June 12, 2026, registering up to 24,868,028 | Jun 15, 2026 |
| FENC | PRESS-RELEASE | neutral | 2/10 | Fennec Pharmaceuticals granted 10,000 incentive stock options to a new non-executive employee at $9.00 per share under i | Jun 15, 2026 |
| AAPG | PRESS-RELEASE | mixed | 6/10 | Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation | Jun 14, 2026 |
| ZYME | PRESS-RELEASE | bullish | 6/10 | Zymeworks presented Phase 1 dose-escalation data for ZW191, an FRα-targeting ADC, at ESMO Gynaecological Cancers Congres | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented positive Phase 2 CAH data at ENDO 2026 showing atumelnant reduced androstenedione by 67% at week 12 | Jun 14, 2026 |
| CRNX | PRESS-RELEASE | bullish | 6/10 | Crinetics presented two-year open-label extension data at ENDO 2026 showing that once-daily oral PALSONIFY (paltusotine) | Jun 14, 2026 |
| MRVI | INST-CLUSTER | mixed | 4/10 | During Q1 2026, six institutional investors increased their MRVI positions (net +$2.3M) while three trimmed (net -$256K) | Jun 14, 2026 |
| CLDX | PRESS-RELEASE | bearish | 6/10 | Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long | Jun 14, 2026 |
| UPB | PRESS-RELEASE | bullish | 7/10 | Upstream Bio presented positive responder analyses from the Phase 2 VIBRANT trial of verekitug in CRSwNP at EAACI 2026, | Jun 14, 2026 |
| CLDX | PRESS-RELEASE | bullish | 7/10 | Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug sh | Jun 14, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T ther | Jun 14, 2026 |
| WLK | INST-CLUSTER | mixed | 5/10 | An institutional cluster in Westlake Corp (WLK) for Q1 2026 reveals a mixed picture: 21 buyers with net inflows of ~$579 | Jun 13, 2026 |
| ASND | PRESS-RELEASE | bullish | 7/10 | Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) | Jun 13, 2026 |
| AGIO | PRESS-RELEASE | mixed | 7/10 | Agios presented detailed Phase 3 RISE UP data for mitapivat in sickle cell disease at EHA 2026, showing statistically si | Jun 13, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported positive Phase 2 data for setmelanotide in Prader-Willi syndrome at ENDO 2026, showing c | Jun 13, 2026 |
| ABT | COURT-RULING | neutral | 4/10 | The court denied plaintiffs' motion for sanctions against Abbott and denied their request to reopen discovery in this in | Jun 13, 2026 |
| NTLA | PRESS-RELEASE | bullish | 8/10 | Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscr | Jun 13, 2026 |
| RKDA | PRESS-RELEASE | bearish | 7/10 | Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds through the sale of co | Jun 12, 2026 |
| PCRX | CLUSTER | neutral | 3/10 | Pacira BioSciences saw two insider sales totaling $372K over a week, including the Chief Administrative Officer and SVP | Jun 12, 2026 |
| SPRY | CLUSTER | neutral | 3/10 | Two C-suite insiders at ARS Pharmaceuticals (SPRY) sold shares on June 12, 2026, totaling $284K in open-market sales. Th | Jun 12, 2026 |
| CTKB | 3 | neutral | 2/10 | Glenn P. Muir filed a Form 3 initial statement of beneficial ownership with Cytek Biosciences, Inc., indicating he has b | Jun 12, 2026 |
| CYRX | CLUSTER | neutral | 4/10 | Two CYRX insiders (CFO and a Director) sold a combined ~$3.12M in open-market shares over a 7-day window, representing ~ | Jun 12, 2026 |
| QURE | CLUSTER | neutral | 3/10 | Two directors sold a combined ~$148K in QURE stock over the past week, with the larger June 11 cluster showing 6 directo | Jun 12, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | 10% owner William P. Scully purchased $1.49M of Prothena stock in two open-market transactions from June 4-11, 2026, at | Jun 12, 2026 |
| QURE | CLUSTER | neutral | 3/10 | Six uniQure insiders (five directors and the chief customer & strategy officer) sold a total of $701K in open-market sal | Jun 12, 2026 |
| TRAW | 8-K | bearish | 7/10 | Traws Pharma disclosed that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been d | Jun 12, 2026 |
| QURE | CLUSTER | neutral | 2/10 | Four uniQure directors sold a total of 7,972 shares for approximately $215,722 on June 11, 2026, all at $27.06 per share | Jun 12, 2026 |